DRREDDY

Dr. Reddy’s Laboratories share price will remain in focus on July 21 following USFDA issued observations to the company's manufacturing facility in Srikakulam, Andhra Pradesh post an inspection. "The United States Food & Drug Administration (USFDA) completed a GMP and a pre-approval inspection (PAI) at formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh, India," company said in its release. The inspection was conducted from July 10 to 18, 2025. The company received a Form 483 with 7 observations, which it will address within the stipulated ***** company is going to announce results for the quarter ended June 30th, 2025 on July 23, 2025 after the board meeting.